Halia Therapeutics to Present Promising Data at Obesity Week 2024

HT-6184 Shows Enhanced and Sustained Weight Loss with GLP-1 Agonist Combination for Obesity LEHI, Utah, October 31, 2024 /PRNewswire/—Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic...

Dr David Bearss Discusses FDA and Safer Cancer Drugs

For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators want them to reconsider that approach.  Companies with cancer drugs in clinical trials must strike a balance between doses high enough to thwart...